Assessing circulating tumor DNA levels prior to initiating neoadjuvant chemoimmunotherapy for locally advanced non-small-cell lung cancer could help to identify patients likely to derive long-term benefit from treatment, suggest exploratory data.
Treatment with carboplatin and pemetrexed plus atezolizumab shows promise for people with nonsquamous non-small-cell lung cancer and asymptomatic, untreated brain metastases, phase 2 study findings indicate.
The ATLANTIS trial has found no significant overall survival improvement with the combination of lurbinectedin and doxorubicin versus chemotherapy in previously treated patients with small-cell lung cancer.
Stereotactic ablative body radiotherapy offers similar outcomes, in terms of toxicity and efficacy, whether it is given as a single fraction or in multiple fractions to patients with up to three lung oligometastases, SAFRON II trial data show.
Antibiotic use does not impair the survival of patients with metastatic non-small-cell lung cancer treated with first-line chemoimmunotherapy, suggest results from an international retrospective study.
Hypofractionated image-guided radiotherapy does not improve survival relative to conventional radiotherapy in patients with stage II or III non-small-cell lung cancer ineligible for concurrent chemoradiotherapy, research shows.
The seropositivity rate in response to the Pfizer–BioNTech (BNT162b2) vaccine against SARS-CoV-2 remains high around 4 months after the second dose in cancer patients undergoing active therapy, report Israeli researchers.
The addition of ipilimumab to nivolumab does not improve the survival outcomes of patients with advanced squamous non-small-cell cancer who have previously received chemotherapy, shows the phase 3 LUNG-MAP S1400I trial.
Smokers who quit after receiving a diagnosis of early-stage non-small-cell lung cancer significantly improve their likelihood of survival relative to those who continue smoking, shows a large prospective cohort study.
Phase 2 study results indicate that savolitinib has promising antitumor activity in Chinese patients with non-small-cell lung cancer harboring MET exon 14 skipping alterations, including those with pulmonary sarcomatoid carcinoma.
Adding perioperative durvalumab to neoadjuvant chemotherapy could be a feasible option for patients with resectable, locally advanced non-small-cell lung cancer with mediastinal lymph node involvement, suggest phase 2 trial data.
A patient-derived tumor fragment platform has allowed close examination of the early immunologic responses to PD-1 blockade, revealing a relationship between immune cell reactivation and clinical response.
Combined treatment with immune checkpoint inhibitors and chemotherapy could be an option for treatment-naïve patients with advanced non-small-cell lung cancer harboring HER2 alterations, suggests a chart review.
Disease recurrence is more likely and overall survival worse for patients with stage I non-small-cell lung cancer who do not receive surgery within 12 weeks of radiographic diagnosis, research suggests.
Adding nivolumab to carboplatin, paclitaxel, and bevacizumab significantly prolongs progression-free survival in people with advanced nonsquamous non-small-cell lung cancer without sensitizing mutations, research shows.
A single dose of the Pfizer-BioNTech vaccine induces high SARS-CoV-2 antibody levels in people with cancer and prior SARS-CoV-2 infection, but immunogenicity is lower in those without previous infection, research shows.